Therapeutic uses of allogeneic myeloid progenitor cells
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorJanice Marie Brown
Life of this patent
Estimating the term…
Abstract
Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.
Claims28
A method of providing myeloid function to a human patient in need thereof, said method comprising:
- transplanting into said human patient a biologically effective dose of allogeneic human myeloid progenitor cells.
Dependencies are inferred from the claim text.